{"id":"trientine-dihydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Iron deficiency anemia"},{"rate":null,"effect":"Systemic lupus erythematosus-like syndrome"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Neurological worsening (initial)"}]},"_chembl":{"chemblId":"CHEMBL3989777","moleculeType":"Small molecule","molecularWeight":"219.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trientine dihydrochloride forms stable complexes with copper ions, facilitating their urinary excretion and reducing free copper levels in tissues. This mechanism is particularly important in Wilson's disease, where defective copper excretion leads to toxic accumulation in the liver, brain, and cornea. By lowering bioavailable copper, trientine prevents progressive neurological, hepatic, and ophthalmologic manifestations.","oneSentence":"Trientine is a copper chelator that binds and removes excess copper from the body, reducing copper-mediated tissue damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:32.505Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wilson's disease (hepatic and neurological manifestations)"},{"name":"Copper toxicity"}]},"trialDetails":[{"nctId":"NCT07465718","phase":"PHASE3","title":"Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.","status":"NOT_YET_RECRUITING","sponsor":"Orphalan","startDate":"2026-05","conditions":"Wilson's Disease","enrollment":38},{"nctId":"NCT07301216","phase":"","title":"Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-08","conditions":"Wilson Disease","enrollment":30},{"nctId":"NCT06430359","phase":"","title":"Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-01-10","conditions":"Wilson Disease","enrollment":30},{"nctId":"NCT07010575","phase":"PHASE2","title":"Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride","status":"COMPLETED","sponsor":"Orphalan","startDate":"2025-07-15","conditions":"Wilson's Disease","enrollment":10},{"nctId":"NCT05783687","phase":"","title":"Real World Evidence Study in Subjects With Wilson's Disease","status":"COMPLETED","sponsor":"Orphalan","startDate":"2023-06-28","conditions":"Wilson Disease","enrollment":50},{"nctId":"NCT04706429","phase":"PHASE2","title":"The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2020-12-01","conditions":"Hypertrophic Cardiomyopathy","enrollment":154},{"nctId":"NCT06128954","phase":"PHASE1","title":"Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).","status":"COMPLETED","sponsor":"Orphalan","startDate":"2024-01-16","conditions":"Wilson's Disease","enrollment":26},{"nctId":"NCT05239858","phase":"","title":"International Wilson's Disease Patient Registry (iWilson Registry)","status":"RECRUITING","sponsor":"Orphalan","startDate":"2022-06-29","conditions":"Wilson's Disease","enrollment":500},{"nctId":"NCT03539952","phase":"PHASE3","title":"Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease","status":"COMPLETED","sponsor":"Orphalan","startDate":"2018-09-03","conditions":"Wilson Disease","enrollment":77},{"nctId":"NCT05047523","phase":"PHASE3","title":"Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-09-13","conditions":"Wilson Disease","enrollment":40},{"nctId":"NCT03403205","phase":"PHASE3","title":"Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-02-22","conditions":"Wilson Disease","enrollment":214},{"nctId":"NCT02763215","phase":"","title":"The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-05-19","conditions":"Wilson Disease","enrollment":64},{"nctId":"NCT03480750","phase":"PHASE1, PHASE2","title":"Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2012-09","conditions":"Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma, Fallopian Tube Cancer","enrollment":18},{"nctId":"NCT03299829","phase":"","title":"A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients","status":"COMPLETED","sponsor":"Excelsior","startDate":"2018-01-10","conditions":"Trientine Treatment for Wilson's Disease","enrollment":48},{"nctId":"NCT01472874","phase":"NA","title":"Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease","status":"COMPLETED","sponsor":"Yale University","startDate":"2010-01","conditions":"Wilson Disease","enrollment":8},{"nctId":"NCT02068079","phase":"PHASE1","title":"A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2014-04","conditions":"Melanoma","enrollment":""},{"nctId":"NCT01295073","phase":"PHASE2","title":"Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"","conditions":"Macular Edema Following Cataract Surgery","enrollment":""},{"nctId":"NCT02426905","phase":"PHASE4","title":"Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine","status":"UNKNOWN","sponsor":"Univar BV","startDate":"2016-01","conditions":"Wilson Disease","enrollment":90},{"nctId":"NCT01178112","phase":"PHASE1","title":"Trientine and Carboplatin in Advanced Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07","conditions":"Advanced Cancers","enrollment":56},{"nctId":"NCT01874028","phase":"PHASE1","title":"A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients","status":"COMPLETED","sponsor":"Univar BV","startDate":"2013-05","conditions":"Wilson's Disease","enrollment":20},{"nctId":"NCT01213888","phase":"NA","title":"Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2010-11","conditions":"Diabetic Retinopathy","enrollment":3},{"nctId":"NCT00004339","phase":"PHASE3","title":"Study of Tetrathiomolybdate in Patients With Wilson Disease","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1994-01","conditions":"Wilson Disease","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pegylated liposomal doxorubicin","carboplatin"],"phase":"marketed","status":"active","brandName":"trientine dihydrochloride","genericName":"trientine dihydrochloride","companyName":"Univar BV","companyId":"univar-bv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trientine is a copper chelator that binds and removes excess copper from the body, reducing copper-mediated tissue damage. Used for Wilson's disease (hepatic and neurological manifestations), Copper toxicity.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":"EMEA/H/C/004111"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Cufence","application_number":null}],"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}